NCT03457935Active, not recruiting
Detection of Early Idiopathic Pulmonary Fibrosis
The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 450 (actual)
- First submitted
- 28 Feb 2018
- Start date
- 10 Apr 2018
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Temple University
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT03457935
What you commit to
- Study type: Observational
- Participants enrolled: 450
- From 10 Apr 2018 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV
- Hepatitis B
- Hepatitis C
Other
- Pregnant or lactating women
Who the study is looking for
- Informed consent
- Subjects ≥ 40 y.o.
- Naive patients with no IPF treatment
- IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria
- Informed consent
- Subjects ≥ 18 y.o.
- ILD diagnosis
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Temple University Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.